Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

MannKind Tops Decade Effort With U.S. Approval of Insulin

June 28 (Bloomberg) -- MannKind Corp. won U.S. approval to sell its inhaled insulin, culminating an almost decade-long effort, with a warning that the product shouldn’t be used by those with asthma or a serious lung disease.

The Food and Drug Administration said yesterday it cleared MannKind’s Afrezza as a fast-acting insulin to be used at meal times for those with Type 1 and Type 2 diabetes. The drug labeling will warn that spasms in the airways of the lung have been seen in patients with asthma and chronic obstructive pulmonary disease and will advise against smokers using the medicine, the agency said in a statement.

“It’s very gratifying,” Chief Financial Officer Matt Pfeffer said in a telephone interview. “We’ve been working toward this moment for a very long time, so we’re thrilled that it’s here.”

Alfred Mann, MannKind’s 88-year-old founder and chief executive officer, took the Valencia, California-based company public in 2004. Since MannKind started late-stage clinical trials eight years ago, the company’s share price has bounced from a high of $21.70 to a low of $1.60, Pfizer Inc. pulled the only inhaled insulin from the market and the FDA twice rejected MannKind’s therapy, most recently in 2011, after the company switched inhalers during the review process.

“It’s good news, and I consider the boxed warning to be a non-event,” Keith Markey, a New York-based analyst at Griffin Securities Inc., said in a telephone interview. “MannKind never wanted to market it to people with COPD.”

Extended Trading

Shares of MannKind gained 10 percent to $11 in extended trading at 6:56 p.m. New York time yesterday after falling 5.5 percent during regular trading to close at $10.

An estimated 25.8 million people in the U.S. have diabetes, a condition in which insulin isn’t naturally produced or used effectively by the body to break down sugar in the blood. The illness can lead to heart disease, blindness and nerve and kidney damage.

MannKind’s drug, a powder, is delivered through a cartridge and is designed to control blood sugar during meal times in less time than standard injections. The FDA said it doesn’t replace long-acting insulin for Type 1 patients, whose bodies don’t naturally produce insulin.

To contact the reporter on this story: Caroline Chen in New York at cchen509@bloomberg.net

To contact the editors responsible for this story: Reg Gale at rgale5@bloomberg.net Andrew Pollack, Angela Zimm

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.